AMNEAL PHARMACEUTICALS, INC. Legal Fees
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Legal Fees of $2.59 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2019-11-07
- AMNEAL PHARMACEUTICALS, INC. legal fees for the quarter ending 2019-09-30 was $2.59M, a 41.24% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. legal fees for the quarter ending 2019-06-30 was $2.51M, a 37.95% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. legal fees for the quarter ending 2019-03-31 was $4.17M, a 8.96% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. legal fees for the quarter ending 2018-12-31 was $3.24M, a 18.48% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. legal fees for fiscal 2018 was $16.26M, a 20.75% decline from fiscal 2017.
- AMNEAL PHARMACEUTICALS, INC. legal fees for fiscal 2017 was $20.52M, a 20.25% decline from fiscal 2016.
- AMNEAL PHARMACEUTICALS, INC. legal fees for fiscal 2016 was $25.73M.
| Period end | Legal Fees 3 month | Legal Fees 6 month | Legal Fees 9 month | Legal Fees 12 month |
|---|---|---|---|---|
| 2019-09-30 | $2.59M 10-Q · filed 2019-11-07 | $5.10M derived: sum of 2 quarters · filed 2019-11-07 | $9.26M 10-Q · filed 2019-11-07 | $12.50M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | $2.51M 10-Q · filed 2019-08-05 | $6.68M 10-Q · filed 2019-08-05 | $9.91M derived: sum of 3 quarters · filed 2019-08-05 | $14.31M derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-03-31 | $4.17M 10-Q · filed 2019-05-09 | $7.40M derived: sum of 2 quarters · filed 2019-05-09 | $11.80M derived: sum of 3 quarters · filed 2019-11-07 | $15.85M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $7.64M derived: sum of 2 quarters · filed 2019-11-07 | $11.69M derived: sum of 3 quarters · filed 2019-11-07 | $16.26M 10-K · filed 2019-03-01 |
| 2018-09-30 | $4.40M 10-Q · filed 2019-11-07 | $8.45M derived: sum of 2 quarters · filed 2019-11-07 | $13.02M 10-Q · filed 2019-11-07 | $15.76M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $4.05M 10-Q · filed 2019-08-05 | $8.62M 10-Q · filed 2019-08-05 | $11.36M derived: sum of 3 quarters · filed 2019-08-05 | $18.05M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | $4.58M 10-Q · filed 2019-05-09 | $7.31M derived: sum of 2 quarters · filed 2019-05-09 | $14.00M derived: sum of 3 quarters · filed 2019-05-09 | $18.93M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $9.43M derived: sum of 2 quarters · filed 2019-03-01 | $14.35M derived: sum of 3 quarters · filed 2019-03-01 | $20.52M 10-K · filed 2019-03-01 |
| 2017-09-30 | $6.69M 10-Q · filed 2018-11-07 | $11.62M derived: sum of 2 quarters · filed 2018-11-07 | $17.79M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $4.93M 10-Q · filed 2018-08-09 | $11.09M 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $25.73M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |